Ozempic lowers blood sugar, promotes weight loss, and protects against heart and kidney complications in people with type 2 diabetes. In clinical trials, it reduced A1C levels by 1.5% to 1.8% over 30 to 56 weeks, which for many people is enough to bring blood sugar from a poorly controlled range into or near the target zone. But blood sugar control is only part of the picture. Ozempic’s benefits extend to several of the most dangerous complications of diabetes.
How Ozempic Works in Your Body
Ozempic (semaglutide) belongs to a class of drugs called GLP-1 receptor agonists. Your gut naturally produces a hormone called GLP-1 after you eat, but your body breaks it down within minutes. Ozempic mimics that hormone in a form that lasts much longer, staying active for a full week after a single injection.
Once active, it does three things simultaneously. First, it signals your pancreas to release more insulin, but only when your blood sugar is actually elevated. This “glucose-dependent” action is important because it means the drug is far less likely to cause dangerously low blood sugar compared to older diabetes medications like sulfonylureas or insulin. Second, it suppresses glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. Third, it slows gastric emptying, meaning food moves through your stomach more gradually. That produces a smaller, more gradual rise in blood sugar after meals and helps you feel full longer.
Blood Sugar and A1C Reduction
The most direct benefit for people with diabetes is better blood sugar control. Across the SUSTAIN clinical trial program, patients taking the 1.0 mg weekly dose saw their A1C drop by 1.5% to 1.8% over roughly 30 to 56 weeks. To put that in perspective, if your A1C starts at 8.5%, that reduction could bring you down to around 7% or below, which is the standard target for most adults with type 2 diabetes.
That level of A1C reduction is comparable to what metformin achieves (about 1.4% in trials), though no head-to-head studies have directly compared the two drugs in the same patients. The American Diabetes Association’s 2026 guidelines now recommend GLP-1 based therapy over insulin as the preferred option for adding glucose-lowering treatment, reflecting how effective and well-tolerated these drugs have proven to be.
Weight Loss in People With Type 2 Diabetes
Weight management is a constant challenge for people with type 2 diabetes, and most older diabetes medications either cause weight gain or are weight-neutral. Ozempic works differently. By slowing digestion and acting on appetite centers in the brain, it reduces hunger in a way that feels natural rather than forced. In studies, participants using GLP-1 medications lost an average of 10% to 15% of their body weight over a year.
For someone weighing 220 pounds, that translates to roughly 22 to 33 pounds. This weight loss isn’t just cosmetic. Losing even 5% to 10% of body weight improves insulin sensitivity, lowers blood pressure, and reduces the strain on joints. It also makes blood sugar easier to manage with less medication over time, creating a positive cycle.
Cardiovascular Protection
Heart disease is the leading cause of death in people with type 2 diabetes, so cardiovascular protection matters as much as blood sugar control. The SUSTAIN-6 trial demonstrated that semaglutide reduces the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in diabetic patients. A later trial called SELECT confirmed a 20% reduction in these events in people with obesity and established heart disease.
Because of this evidence, the American Diabetes Association now recommends that adults with type 2 diabetes who have or are at high risk for cardiovascular disease should be on a GLP-1 receptor agonist regardless of their A1C level. In other words, even if your blood sugar is already well controlled, Ozempic may still be recommended for its heart-protective effects.
Kidney Disease Protection
Diabetes is the most common cause of chronic kidney disease, and until recently, treatment options for slowing that decline were limited. The FLOW trial, which enrolled over 3,500 patients with type 2 diabetes and significant kidney disease, found that semaglutide reduced the risk of major kidney events by 24%. The trial was actually stopped early because the benefit was so clear.
Patients on semaglutide also lost kidney function more slowly, preserving about 1.16 mL/min per year of filtering capacity compared to placebo. That may sound small, but over years it can mean the difference between stable kidney function and needing dialysis. Current guidelines recommend GLP-1 receptor agonists for diabetic patients with chronic kidney disease, and they’re now the preferred option for blood sugar management in advanced kidney disease where other medications carry higher risks.
How Ozempic Is Taken
Ozempic is a once-weekly injection you give yourself using a prefilled pen, typically in the abdomen, thigh, or upper arm. The dose is gradually increased to reduce side effects. You start at 0.25 mg weekly for four weeks. That starting dose isn’t meant to control blood sugar; it’s purely to let your body adjust. After four weeks, you move up to 0.5 mg. If you need more blood sugar control after at least another four weeks, your dose can be increased to the maximum of 1 mg weekly.
Most people settle into a routine quickly. You pick the same day each week and can inject at any time of day, with or without food.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects, and they’re a direct consequence of how the drug works. Slowing gastric emptying helps with blood sugar and appetite, but it can also cause discomfort, especially early on. Across clinical studies of GLP-1 receptor agonists, about 21% of patients experienced nausea, 11% had diarrhea, 9% experienced vomiting, and roughly 8% reported indigestion or constipation.
These side effects are typically worst during the first few weeks and during dose increases, then fade as your body adjusts. The gradual dose titration schedule exists specifically to minimize this window of discomfort. Eating smaller meals, avoiding high-fat foods, and stopping eating when you feel full (rather than finishing a plate) all help.
Serious Risks to Know About
Ozempic carries an FDA boxed warning about thyroid cancer. In animal studies, GLP-1 receptor agonists caused thyroid tumors, specifically a type called medullary thyroid carcinoma. Whether this risk applies to humans isn’t established, but the drug is not prescribed to anyone with a personal or family history of medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2.
There is also a small risk of acute pancreatitis. Symptoms include severe, persistent abdominal pain that may radiate to the back, sometimes with vomiting. If you experience this, you should stop taking the medication and seek medical attention. The overall incidence is low, but it’s the reason providers ask about any history of pancreatitis before prescribing.
Liver Disease Benefits
An increasingly recognized benefit is Ozempic’s effect on fatty liver disease, which affects a large proportion of people with type 2 diabetes. The ADA’s 2026 guidelines now recommend GLP-1 receptor agonists for diabetic patients who also have metabolic liver disease and overweight or obesity. For those with biopsy-confirmed liver inflammation and scarring, a GLP-1 receptor agonist is the preferred diabetes medication specifically because of its beneficial effects on the liver.
This makes Ozempic unusual among diabetes drugs: rather than simply lowering blood sugar while you manage complications separately, it directly addresses several of the organ systems that diabetes damages most.